An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
QTc interval
2-4 days postdose
Yes
Naomi Hunder, MD
Study Director
Seattle Genetics, Inc.
United States: Food and Drug Administration
SGN35-007
NCT01026233
January 2010
August 2011
Name | Location |
---|---|
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
City of Hope National Medical Center | Los Angeles, California 91010 |
Baylor University Medical Center | Dallas, Texas 75246 |
Stanford Cancer Center | Stanford, California 94305-5824 |
University of Alabama at Birmingham | Birmingham, Alabama 35294-3300 |
New York University Cancer Institute | New York, New York 10016 |
University of Miami Hospital and Clinics, Miller School of Medicine | Miami, Florida 33136 |
Cardinal Bernardin Cancer Center / Loyola University Medical Center | Maywood, Illinois 60153 |